Obsidian Therapeutics, Inc. (OBX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Obsidian Therapeutics, Inc. (OBX) closed at USD 12.22 on 2026-10-14, a change of -30.2 % over the past year, with a market capitalization of USD 753.63M.

Obsidian Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Obsidian Therapeutics, Inc. key figures

Previous close

USD 12.22 (2026-10-14)

1-year change

-30.2 %

Market cap

USD 753.63M

Enterprise value

USD 1.05B

P/E ratio (trailing)

-7.31

P/E ratio (forward)

-5.73

EPS (trailing)

-1.67

EPS (forward)

-2.13

PEG ratio

n/a

Price to book

-0.90

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

1.33

Employees

87

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Obsidian Therapeutics, Inc. and compare it with other stocks.